2020 Liver Meeting
Fatty Acid Blocker Does Well in Phase 2 Trial for NASH
The inhibition of fatty acid synthase inhibition may hold promise as a therapy for patients with nonalcoholic ...
MAY 24, 2021
QI Project Aims to Reduce Variability in Varices Care
Adherence to published surveillance guidelines for esophageal varices in patients with cirrhosis can be bolstered ...
MAY 20, 2021
Expert Picks From The 2020 Liver Meeting
In this edition of “Expert Picks,” Ashwani K. Singal, MD, MS, identifies significant research in ...
MARCH 5, 2021
For Alcohol Abuse, Early Research Shows Promise of FMT
Fecal microbiota transplantation appeared safe and beneficial in a small study of men with alcohol use disorder and ...
FEBRUARY 19, 2021
Clinic Model Reduces Cirrhosis Readmissions
Liver specialists have long been frustrated by trying to keep patients with cirrhosis out of the hospital.
FEBRUARY 12, 2021
